Trial Profile
An Extension Study of Iron Chelation Therapy With Deferasirox (ICL670)in β-thalassemia Patients With Transfusional Iron Overload
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 03 Oct 2021
Price :
$35
*
At a glance
- Drugs Deferasirox (Primary)
- Indications Beta-thalassaemia; Iron overload
- Focus Adverse reactions
- Sponsors Novartis Pharmaceuticals Corporation
- 10 Sep 2014 New trial record